NeoGenomics Inc 2023 SR
The report marks NeoGenomics' inaugural ESG disclosure, highlighting its commitment to advancing cancer care through sustainable practices. In 2023, the company conducted its first double materiality assessment and established a Diversity, Equity, Inclusion, and Belonging (DEIB) Council. Key environmental achievements include reporting Scope 1 and 2 emissions for major sites and achieving LEED certification for its Florida headquarters. The company also reported that 59.9% of its workforce is female and 33.3% of its independent board members are women. Furthermore, NeoGenomics served over 600,000 patients and processed approximately 1.2 million tests during the year.
Company: NeoGenomics Inc
Sector: Healthcare & social services
Country: United States
Year: 2023
Type: SR
Pages: 46
NeoGenomics Inc
The report marks NeoGenomics' inaugural ESG disclosure, highlighting its commitment to advancing cancer care through sustainable practices. In 2023, the company conducted its first double materiality assessment and established a Diversity, Equity, Inclusion, and Belonging (DEIB) Council. Key environmental achievements include reporting Scope 1 and 2 emissions for major sites and achieving LEED certification for its Florida headquarters. The company also reported that 59.9% of its workforce is female and 33.3% of its independent board members are women. Furthermore, NeoGenomics served over 600,000 patients and processed approximately 1.2 million tests during the year.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 1, 2023 - Dec 31, 2023
Fiscal Year
2023
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Employees